Reported 6 days ago
Insulet Corporation has seen a significant increase in interest in its Omnipod Insulin Management System, designed for Type 2 diabetes patients. The device, which offers pain-free insertion and integrates with blood glucose meters, has experienced a 25% revenue growth in Q3 2024, largely due to adoption in the U.S. and international sales. With robust cash reserves and strong institutional support, PODD shares have risen 22% this year, indicating a promising outlook for future growth.
Source: YAHOO